ES2051859T3 - Inmunoensayo en fase solida para un anticuerpo y estructuras biologicas para uso en el mismo. - Google Patents

Inmunoensayo en fase solida para un anticuerpo y estructuras biologicas para uso en el mismo.

Info

Publication number
ES2051859T3
ES2051859T3 ES88308170T ES88308170T ES2051859T3 ES 2051859 T3 ES2051859 T3 ES 2051859T3 ES 88308170 T ES88308170 T ES 88308170T ES 88308170 T ES88308170 T ES 88308170T ES 2051859 T3 ES2051859 T3 ES 2051859T3
Authority
ES
Spain
Prior art keywords
antibody
solid phase
sequence
amino acids
immuno assay
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES88308170T
Other languages
English (en)
Inventor
Peter Edmund Highfield
Richard Julian Stuart Duncan
David Parker
Robert Paul Spence
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
International Murex Technologies Corp
Original Assignee
International Murex Technologies Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26292688&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2051859(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB878720800A external-priority patent/GB8720800D0/en
Priority claimed from GB888818030A external-priority patent/GB8818030D0/en
Application filed by International Murex Technologies Corp filed Critical International Murex Technologies Corp
Application granted granted Critical
Publication of ES2051859T3 publication Critical patent/ES2051859T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

UN INMUNOENSAYO DE UN ANTICUERPO COMPRENDE: (I) PONER EN CONTACTO UNA FASE SOLIDA SOBRE LA QUE SE INMOVILIZA UN PRIMER PEPTICO RECOMBINANTE, QUE PRESENTA UNA SECUENCIA ANTIGENA A LA QUE ES CAPAZ DE UNIRSE EL ANTICUERPO, CON UNA MUESTRA DE ENSAYO; (II) PONER EN CONTACTO LA FASE SOLIDA CON UN SEGUNDO PEPTIDO RECOMBINANTE, QUE PRESENTA DICHA SECUENCIA ANTIGENA, QUE ESTA ETIQUETADO Y QUE ESTABA EXPRESADO EN UN ORGANISMO DE GENERO DIFERENTE DE AQUEL EN EL QUE ESTABA EXPRESADO EL PRIMER PEPTIDO RECOMBINANTE; (III) DETERMINAR SI LA MUESTRA DE ENSAYO CONTIENE DICHO ANTICUERPO. UNA PROTEINA ADECUADA PARA USAR EN ENSAYO DE ANTICUERPO ANTI-P24 Y ANTI-GP41 HIV-1 ES UNA FUSION DE UNA SECUENCIA GAP QUE COMPRENDE AMINOACIDOS 121-356 Y UNA SECUENCIA ENV QUE COMPRENDE AMINOACIDOS 542-674. LOS AMINOACIDOS SE NUMERAN DE ACUERDO CON MEUSING Y OTROS, NATURE, 313, 450-458 (1985).
ES88308170T 1987-09-04 1988-09-02 Inmunoensayo en fase solida para un anticuerpo y estructuras biologicas para uso en el mismo. Expired - Lifetime ES2051859T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB878720800A GB8720800D0 (en) 1987-09-04 1987-09-04 Immunoassay
GB888818030A GB8818030D0 (en) 1988-07-28 1988-07-28 Fusion constructs

Publications (1)

Publication Number Publication Date
ES2051859T3 true ES2051859T3 (es) 1994-07-01

Family

ID=26292688

Family Applications (1)

Application Number Title Priority Date Filing Date
ES88308170T Expired - Lifetime ES2051859T3 (es) 1987-09-04 1988-09-02 Inmunoensayo en fase solida para un anticuerpo y estructuras biologicas para uso en el mismo.

Country Status (10)

Country Link
EP (1) EP0307149B1 (es)
JP (1) JP2634203B2 (es)
AU (1) AU615670B2 (es)
CA (1) CA1341343C (es)
DE (1) DE3877294T2 (es)
DK (1) DK490888A (es)
ES (1) ES2051859T3 (es)
IE (1) IE63455B1 (es)
NZ (1) NZ226026A (es)
PT (1) PT88416B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0313986B1 (en) * 1987-10-30 1995-12-27 Abbott Laboratories Immunoassays using antigens produced in heterologous organisms
US5254458A (en) * 1987-10-30 1993-10-19 Abbott Laboratories Immunoassays using antigens produced in heterologous organisms
DE3854550T2 (de) * 1987-11-24 1996-04-25 Abbott Lab HIV-Peptide und Methoden für den Nachweis von HIV.
US5204259A (en) * 1988-05-06 1993-04-20 Pharmacia Genetic Engineering, Inc. Methods and systems for producing HIV antigens
DE68917520T2 (de) * 1988-05-06 1995-01-05 Ferropas Ag Verfahren und Systeme zur Herstellung von HIV-Antigenen.
CA2084386C (en) * 1992-06-04 2001-02-20 Atsushi Saito Hiv antigen
WO1995016040A2 (en) * 1993-12-10 1995-06-15 The Canadian Red Cross Society Immunofluorescence assay for the detection of antibodies using recombinant antigens in insoluble form
DE4405810A1 (de) 1994-02-23 1995-08-24 Behringwerke Ag Von einem Retrovirus aus der HIV-Gruppe abgeleitete Peptide und deren Verwendung
WO1996003652A1 (de) * 1994-07-25 1996-02-08 Boehringer Mannheim Gmbh Bestimmung von spezifischem immunglobulin unter verwendung multipler antigene
WO1996003651A1 (de) 1994-07-25 1996-02-08 Boehringer Mannheim Gmbh Metallchelat-markierte peptide
DE4430972A1 (de) * 1994-07-25 1996-02-01 Boehringer Mannheim Gmbh Bestimmung von spezifischem Immunglobulin unter Verwendung multipler Antigene
ES2165042T3 (es) * 1996-03-15 2002-03-01 Univ Southern California Vacuna que contiene el virus de la artritis-encefalitis de cabra y utilizacion para inmunoproteccion contra la infeccion por hiv-1.
DE19649390A1 (de) 1996-11-29 1998-06-04 Boehringer Mannheim Gmbh Antigenspezifischer IgG-Nachweis
DE19723463A1 (de) * 1997-06-04 1998-12-10 Dade Behring Marburg Gmbh Immunchemische Bestimmung von multivalenten Analyten
NO311807B1 (no) 1999-03-04 2002-01-28 Bionor Immuno As HIV-peptider, antigener, vaksinepreparater, immunoassay- testsett og en metode for påvisning av antistoffer fremkalt av HIV
DE10106295C1 (de) * 2001-02-02 2002-08-22 Gaifar German American Inst Fo Protein mit mehreren Antigen-Epitop-Sequenzen, welches immobilisiert ist

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6061534A (ja) * 1983-09-16 1985-04-09 Kyowa Hakko Kogyo Co Ltd 成人ｔ細胞白血病ウイルス抗原ペプチド
EP0152030A3 (en) * 1984-02-03 1986-08-13 Juridical Foundation Japanese Foundation for Cancer Research Adult t cell leukemia virus antigen polypeptide
CA1341482C (en) * 1984-10-31 2005-05-10 Paul A. Luciw Process for preparing fragments of aids-associated retroviruses
ATE138100T1 (de) * 1984-12-24 1996-06-15 Genentech Inc Fusionen von aids-verwandten polypeptiden
GB2179449B (en) * 1985-01-15 1988-12-21 Cancer Res Inst Improvements relating to viral isolates and their use
KR910002374B1 (ko) * 1985-04-29 1991-04-20 제네틱 시스템즈 코포레이션 Aids 관련질병의 검출을 위한 합성항원
JP2564268B2 (ja) * 1985-08-28 1996-12-18 協和醗酵工業株式会社 融合抗原ポリペプチド
US4748110A (en) * 1985-09-25 1988-05-31 Abbott Laboratories Immunoassay for HTLV-III antigens
FI853760A7 (fi) * 1985-09-30 1987-03-31 Tampella Oy Ab Menetelmä poratyökalun ohjaamiseksi kallioporauksessa.
US4925784A (en) * 1986-04-04 1990-05-15 Hoffmann-La Roche Inc. Expression and purification of an HTLV-III gag/env gene protein
AU1334588A (en) * 1987-03-23 1988-09-22 Ortho Pharmaceutical Corporation Assay for detecting hepatitis antigens and aids antibodies

Also Published As

Publication number Publication date
IE63455B1 (en) 1995-04-19
EP0307149B1 (en) 1993-01-07
AU2182588A (en) 1989-03-09
NZ226026A (en) 1991-03-26
DE3877294D1 (de) 1993-02-18
IE882658L (en) 1989-03-04
DK490888A (da) 1989-03-05
CA1341343C (en) 2002-02-26
DK490888D0 (da) 1988-09-02
PT88416B (pt) 1992-10-30
PT88416A (pt) 1989-07-31
JP2634203B2 (ja) 1997-07-23
EP0307149A2 (en) 1989-03-15
DE3877294T2 (de) 1993-05-06
EP0307149A3 (en) 1989-05-03
JPH01163665A (ja) 1989-06-27
AU615670B2 (en) 1991-10-10

Similar Documents

Publication Publication Date Title
ES2064316T3 (es) Composicion de peptido y procedimiento para la deteccion de anticuerpos frente al htlv-iii.
SE8704185L (sv) Nya peptider, artificiella antigener och immunoanalystestsatser
BRPI0210598B8 (pt) processos para a produção de um complexo solúvel que compreende uma proteína amiloidogênica alvo e uma chaperona peptidil-prolil-isomerase, para a produção de um complexo de glicoproteína retroviral de superfície-chaperona solúvel, e para detectar pelo menos um anticorpo para uma glicoproteína retroviral de superfície em uma amostra, bem como complexo solúvel, e composição
EA200100943A1 (ru) Вич-пептиды, антигены, вакцинные композиции, набор для иммуноанализа и способ определения вич-индуцированных антител
DE69827642D1 (de) Schnelltest zur gleichzeitigen spezifischen bestimmung von hiv-antikörpern
EP1475442A3 (en) Polypeptides of feline T-cell lymphotropic lentivirus
DE60331677D1 (de) Kit zur untersuchung von menschlichem niedermolekulargewicht cd14 und antikörper
PE20030065A1 (es) Metodos para administrar anticuerpos anti-tnfalfa
KR950008537A (ko) 엡스타인 바 비루스(ebv)에 대한 항체의 검출용 진단제
DE69840445D1 (de) Antigen-konstrukte, für den nachweis und die unterscheidung von antikörpern gegen hiv
ES2159291T3 (es) Metodo y analisis de htlv-i/htlv-ii.
ES2054769T3 (es) Polipeptidos hiv-2 recombinantes.
ATE116660T1 (de) Künstliche peptid-zusammensetzungen mit immunoreaktiven antikörpern von htlv-1.
BR8907452A (pt) Peptideo e polipeptideo antifilicos,processo e composicao para sua utilizacao
ES2113356T3 (es) Peptidos con un determinante antigenico caracteristico para alfa-1-micro-globulina.
ES2058259T5 (es) Antigenos sinteticos para la deteccion de enfermedad relacionada con sida causada por lav-2.
ATE163765T1 (de) Bindendes protein fixierungstest.
HUP9800782A2 (hu) Új antitest, az azt tartalmazó renin-aktív anyag és a prorenin vizsgálatára szolgáló reagens
DK0550691T3 (da) Antistofinducerende peptider, som inhiberer retrovira af HIV-typen, og antistoffer, som er specifikke for disse peptider
FI102834B1 (fi) Kysteiinitioli-suojatut peptidit käytettäviksi immunologisissa määrityksissä
ES2019573T3 (es) Inmunoensayo para la deteccion de alfa-haloacetamidas.
WO2004092724A3 (en) Multiple antigenic peptide assay for detection of hiv or siv type retroviruses
KR910007962A (ko) Hiv 관련 펩티드
KR900003204A (ko) Hiv-항체와 면역화학적으로 반응성 있는 합성 펩티드
ES2110283T3 (es) Proteinas y glicoproteinas de anticuerpos de los retrovirus hiv-2 eho dirigidos contra ellos - aplicacion para la diagnosis.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 307149

Country of ref document: ES